ChemotherapyFDA-approvedSecond-line
Lonsurf
Generic name: trifluridine/tipiracil
How it works
Interferes with DNA replication and blocks the action of a protein that helps cancer cells repair DNA damage.
Cancer types
Colorectal Cancer— All patients
Efficacy
In clinical trials, Lonsurf improved overall survival and response rates in patients with metastatic colorectal cancer who have not responded to other treatments.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Treatment Combination Shows Promise for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | The objective response rate was 18.3%, and the disease control rate was 83.3%. | Source → |
| Trifluridine/Tipiracil Treatment in Metastatic Colorectal Cancer | Colorectal Cancer | observational | Median overall survival was 7.59 months. | Source → |
| Trifluridine/Tipiracil Combinations Show Promise in Advanced Colorectal Cancer | Colorectal Cancer | review | Median overall survival ranged 8.6-14.4 months and median progression-free survival 3.7-6.8 months with FTD/TPI plus bevacizumab in refractory mCRC. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.